Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 6/20 | 0.41 |
| ▸ | AURKA | O14965 | 4/20 | 0.41 |
| ▸ | BRD4 | O60885 | 5/20 | 0.41 |
| ▸ | CCND3 | P30281 | 4/20 | 0.39 |
| ▸ | CCNK | O75909 | 2/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | CDK9 | P50750 | 2/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.38 |
| ▸ | CCND1 | P24385 | 2/20 | 0.38 |
| ▸ | CCND2 | P30279 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 3/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.37 |
| ▸ | MARK3 | P27448 | 1/20 | 0.37 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.37 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.37 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.37 |
| ▸ | MARK1 | Q9P0L2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3590043 | 0.81 | CDK4 (0.57) | CDK4AURKACCND3CCNKCCNA2 | |
| SCHEMBL3577564 | 0.81 | CDK4 (0.57) | CDK4AURKACCND3CCNKCCNA2 | |
| SCHEMBL3577561 | 0.81 | CDK4 (0.57) | CDK4AURKACCND3CCNKCCNA2 | |
| SCHEMBL3585957 | 0.80 | CDK4 (0.51) | CDK4AURKACCND3CCNA2CDK2 | |
| SCHEMBL3588421 | 0.79 | CDK4 (0.46) | CDK4AURKACCND3CCNA2CDK2 | |
| SCHEMBL3583817 | 0.78 | CDK4 (0.52) | CDK4AURKACCND3CCNKCCNA2 | |
| SCHEMBL3579088 | 0.78 | CDK4 (0.52) | CDK4AURKACCND3CCNKCCNA2 | |
| SCHEMBL3579086 | 0.78 | CDK4 (0.52) | CDK4AURKACCND3CCNKCCNA2 | |
| SCHEMBL3592565 | 0.78 | CDK4 (0.55) | CDK4CCND3CCNA2CDK2CDK6 | |
| SCHEMBL3586598 | 0.78 | CDK4 (0.55) | CDK4CCND3CCNA2CDK2CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2108019-A2 | 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | Biogen Idec MA, Inc. (US) | 2009-10-14 | — | — | EP | claimed |
| WO-2008094575-A2 | 1-H-PYRAZOLO(3,4B)PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | BIOGEN IDEC MA INC. (US) | 2008-08-07 | — | — | WO | claimed |
| US-20100190787-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190787-A1 | Modulators of Mitotic Kinases | CDK1, BUB1, BUB1B | CDK4 102/4885AURKA 10/4885BRD4 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.